Chi-Heng Wu

4PUBLICATIONS
35CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Allergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Apr 26, 2024
HPN328, a Trispecific T Cell-Activating Protein Construct Targeting DLL3-Expressing Solid Tumors.

Mary E Molloy, Wade H Aaron, Manasi Barath

|Nov 28, 2019
Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.

Khoan Vu, Chi-Heng Wu, Chen-Yen Yang

Pageof 1